Table 3. Summary of treatment in seven PPCL and two SPCL patients.
a)Not affordable for bortezomib.
Note: Among ten PPCLs, one lost follow-up before start of therapy and two opted against therapy. Out of four SPCLs, two opted against therapy.
Abbreviations: PPCL, primary plasma cell leukemia; SPCL, secondary plasma cell leukemia; CR, complete response; PR, partial response; sCR, stringent CR.